PENS or TENS for Pain in Liver Cancer
Primary Purpose
Pain, Cancer Pain, Liver Neoplasms
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
PENS
TENS
Sponsored by
About this trial
This is an interventional treatment trial for Pain focused on measuring percutaneous electrical nerve stimulation, transcutaneous electrical nerve stimulation, pain, liver cancer, hepatocellular carcinoma
Eligibility Criteria
Inclusion Criteria:
- Primary liver cancer with pain;
- Haven't underwent neurolytic celiac plexus block in the past 1 month;
- With anticipatory survival of more than 3 months.
Exclusion Criteria:
- Metastatic liver cancer;
- Can not tolerate a flat or side lying or sitting prostrate for 30 min;
- performance score>3;
- Who has been recruited in other clinical trial for pain relieving;
- Who underwent radiotherapy or local radioactive seeds implantation for pain relieving in the past month;
- Imaging diagnosed with encephalic tumor or metastasis;
- Who with cardiac pacemaker or metal stand;
Sites / Locations
- Fuda Cancer Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
No Intervention
Arm Label
percutaneous stimulation
transcutaneous stimulation
Control
Arm Description
PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
Conventional analgesic medication is offered.
Outcomes
Primary Outcome Measures
pain score
pain score assessed via visual analogue scale (VAS)
Secondary Outcome Measures
quantity of analgesic medication
decreasing in quantity of analgesic medication
times of breakthrough pain (BTP)
times of BTP per day
Full Information
NCT ID
NCT03338543
First Posted
October 31, 2017
Last Updated
September 10, 2019
Sponsor
Fuda Cancer Hospital, Guangzhou
1. Study Identification
Unique Protocol Identification Number
NCT03338543
Brief Title
PENS or TENS for Pain in Liver Cancer
Official Title
Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Liver Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
November 1, 2017 (Actual)
Primary Completion Date
April 30, 2018 (Actual)
Study Completion Date
August 30, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fuda Cancer Hospital, Guangzhou
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and transcutaneous nerve stimulation (TENS) for pain relieving in patients with liver cancer. Patients will randomly allocated into PENS group, Tens group and control group.
Detailed Description
PENS and TENS have been reported with analgesic effect in patients with pain, including cancer pain, lower back pain, neck pain, stomachache and so on. Effect and mechanism of PENS on pain relieving has been widely researched. With additional electrical stimulation in certain frequency and intensity to conventional acupuncture, pain controlling effect has been largely enhanced. However, invasive operation limits its application and acceptability, especially on pancreatic cancer. TENS is an advanced technique generated from PENS, which is much more welcome for its noninvasive character. Further more, its analgesic effect on cancer pain has been proved by several multi-central, randomized, clinical trials.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Cancer Pain, Liver Neoplasms
Keywords
percutaneous electrical nerve stimulation, transcutaneous electrical nerve stimulation, pain, liver cancer, hepatocellular carcinoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
patients with liver cancer pain.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Participant is allocated randomly by staff A, and grouping situation is concealed; Technician (stuff B) or chargeing docotor operates PENS or TENS, or administers oral analgesic medication; Related datas are collected according to perdetermined forms by stuff C; Outcomes are assessed by stuff D.
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
percutaneous stimulation
Arm Type
Experimental
Arm Description
PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
Arm Title
transcutaneous stimulation
Arm Type
Experimental
Arm Description
TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Conventional analgesic medication is offered.
Intervention Type
Device
Intervention Name(s)
PENS
Intervention Description
percutaneous electrical nerve stimulation
Intervention Type
Device
Intervention Name(s)
TENS
Intervention Description
transcutaneous electrical nerve stimulation
Primary Outcome Measure Information:
Title
pain score
Description
pain score assessed via visual analogue scale (VAS)
Time Frame
day0 to day6
Secondary Outcome Measure Information:
Title
quantity of analgesic medication
Description
decreasing in quantity of analgesic medication
Time Frame
day0 to Day6
Title
times of breakthrough pain (BTP)
Description
times of BTP per day
Time Frame
day0 to day6
Other Pre-specified Outcome Measures:
Title
complications
Description
any correlated complications happen during procedure
Time Frame
day1 to day3
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Primary liver cancer with pain;
Haven't underwent neurolytic celiac plexus block in the past 1 month;
With anticipatory survival of more than 3 months.
Exclusion Criteria:
Metastatic liver cancer;
Can not tolerate a flat or side lying or sitting prostrate for 30 min;
performance score>3;
Who has been recruited in other clinical trial for pain relieving;
Who underwent radiotherapy or local radioactive seeds implantation for pain relieving in the past month;
Imaging diagnosed with encephalic tumor or metastasis;
Who with cardiac pacemaker or metal stand;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lizhi Niu, Dr.
Organizational Affiliation
Fuda Cancer Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Fuda Cancer Hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510665
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
22419313
Citation
Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006276. doi: 10.1002/14651858.CD006276.pub3.
Results Reference
background
PubMed Identifier
26121600
Citation
Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015 Jun 29;2015(6):CD009389. doi: 10.1002/14651858.CD009389.pub3.
Results Reference
background
PubMed Identifier
24280575
Citation
Chen H, Liu TY, Kuai L, Zhu J, Wu CJ, Liu LM. Electroacupuncture treatment for pancreatic cancer pain: a randomized controlled trial. Pancreatology. 2013 Nov-Dec;13(6):594-7. doi: 10.1016/j.pan.2013.10.007. Epub 2013 Oct 23.
Results Reference
background
PubMed Identifier
26468973
Citation
Paley CA, Johnson MI, Tashani OA, Bagnall AM. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2015 Oct 15;2015(10):CD007753. doi: 10.1002/14651858.CD007753.pub3.
Results Reference
background
Learn more about this trial
PENS or TENS for Pain in Liver Cancer
We'll reach out to this number within 24 hrs